文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

低危前列腺癌大分割与标准分割质子治疗的随机3期试验:初始毒性、生活质量结局与剂量学影响

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer.
PubMed 文献 · Adv Radiat Oncol · 2018-02-23

该随机3期试验 interim 分析前75例低危前列腺癌患者,比较38 Gy RBE/5次(n=46)与79.2 Gy RBE/44次(n=29)质子治疗,中位随访36个月。两组≥2级泌尿生殖毒性相似(34.5% vs 30.4%,P=.80),38 Gy组早期AUASI和EPIC泌尿症状评分较差但≥18个月时差异消失;膀胱V80(79.2 Gy组)和V39(38 Gy组)可预测累积≥2级泌尿生殖不良事件。

要点

  • 两组≥2级泌尿生殖毒性相似:79.2 Gy组34.5% vs 38 Gy组30.4%(P=.80)。
  • 1年时AUASI评分38 Gy组4.4 vs 79.2 Gy组8.6(P=.002),79.2 Gy组更优,但≥18个月无显著差异。
  • 膀胱V80(79.2 Gy组,P=.04)和V39(38 Gy组,P=.05)可预测累积≥2级泌尿生殖不良事件。

核心结论

  • 两个治疗组不良事件发生率均较低。
  • 泌尿生殖评分早期暂时性差异随时间消失。
  • 膀胱约束与泌尿生殖不良事件相关。

研究设计与样本

  • 随机3期试验的 interim 分析,纳入前75例低危前列腺癌患者。
  • 比较38 Gy RBE/5次(n=46)与79.2 Gy RBE/44次(n=29)质子治疗,随机分配比例2:1 favoring 38 Gy RBE组。
  • 患者接受质子放疗,使用基准标记和每日影像引导。
  • 评估AUASI、不良事件和EPIC各领域。
  • 本次 interim 分析的主要终点为≥2级不良事件的累积发生率。

主要发现

  • 中位随访36个月,30%患者达到48个月随访。
  • 1年时AUASI评分差异<5分:38 Gy组4.4 vs 79.2 Gy组8.6(P=.002),79.2 Gy组更优;≥18个月时AUASI差异无统计学意义。
  • EPIC泌尿症状1年时38 Gy组84.5 vs 79.2 Gy组92.3(P=.009),18个月时38 Gy组85.3 vs 79.2 Gy组92.3(P=.03),均79.2 Gy组更优;其他时间点困扰评分无显著差异。
  • 累积≥2级泌尿生殖毒性79.2 Gy组34.5% vs 38 Gy组30.4%(P=.80),两组相似。
  • EPIC肠道症状、性症状领域及≥2级肠道毒性均无差异。

关键数值与推荐

  • 38 Gy RBE分5次 vs 79.2 Gy RBE分44次。
  • ≥2级泌尿生殖毒性累积发生率79.2 Gy组34.5% vs 38 Gy组30.4%(P=.80)。
  • AUASI评分1年时38 Gy组4.4 vs 79.2 Gy组8.6(P=.002)。
  • EPIC泌尿症状1年时38 Gy组84.5 vs 79.2 Gy组92.3(P=.009),18个月时38 Gy组85.3 vs 79.2 Gy组92.3(P=.03)。
  • 膀胱V80(79.2 Gy组)预测累积≥2级泌尿生殖不良事件P=.04,膀胱V39(38 Gy组)P=.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Randomized evidence for extreme hypofractionation in prostate cancer is lacking. We aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and extreme hypofractionated radiation in a phase 3 randomized trial. METHODS AND MATERIALS: We analyzed the results of the first 75 patients in our phase 3 trial, comparing 38 Gy relative biologic effectiveness (RBE) in 5 fractions (n = 46) versus 79.2 Gy RBE in 44 fractions (n = 29). Patients received proton radiation using fiducials and daily image guidance. We evaluated American Urological Association Symptom Index (AUASI), adverse events (AEs), and Expanded Prostate Index Composite (EPIC) domains. The primary endpoint of this interim analysis was the cumulative incidence of grade 2 (G2) or higher AEs. The randomized patient allocation scheme was a 2:1 ratio favoring the 38 Gy RBE arm. RESULTS: The median follow-up was 36 months; 30% of patients reached 48-month follow-up. AUASI scores differed <5 points (4.4 vs 8.6; P = .002) at 1 year, favoring the 79.2 Gy arm. Differences in AUASI were not significant at ≥18 months. EPIC urinary symptoms favored the 79.2 Gy arm at 1 year (92.3 vs 84.5; P = .009) and 18 months (92.3 vs 85.3; P = .03); bother scores were not significant at other time points. Cumulative ≥G2 genitourinary toxicity was similar between the 79.2 Gy and 38 Gy arms (34.5% vs 30.4%; P = .80). We found no differences in the EPIC domains of bowel symptoms, sexual symptoms, or bowel ≥G2 toxicities. Bladder V80 (79.2 Gy arm; P = .04) and V39 (38 Gy arm; P = .05) were predictive for cumulative G2 genitourinary AEs. CONCLUSIONS: Low AE rates were seen in both study arms. Early temporary differences in genitourinary scores disappeared over time. Bladder constraints were associated with genitourinary AEs.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vargas CE, Schmidt MQ, Niska JR, et al. Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer. Adv Radiat Oncol. 2018. PMID: 30202801. doi:10.1016/j.adro.2018.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。